PMID-26597252 – Liraglutide Clinical Pharmacokinetics and Pharmacodynamics
Jacobsen LV, Flint A, Olsen AK, Ingwersen SH. Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics. Clin Pharmacokinet. 2016;55(6):657-72.
Quick Reference
| Property | Value |
|---|---|
| PMID | 26597252 |
| DOI | 10.1007/s40262-015-0343-6 |
| Year | 2016 |
| Journal | Clinical Pharmacokinetics |
| Study Type | Narrative Review (Pharmacology) |
| Evidence Level | V |
| Sample | Review of multiple clinical pharmacology studies |
| Peptide(s) Studied | Liraglutide |
Key Findings
- Structural modification: Liraglutide is a modified GLP-1 (7-37) analog with 97% amino acid sequence homology to native GLP-1. Key modifications: Arg34 substitution (lysine to arginine at position 34) and attachment of a C-16 palmitic acid (palmitoyl) fatty acid chain via a glutamic acid spacer at Lys26
- Albumin binding: The C-16 fatty acid enables reversible non-covalent binding to serum albumin (>98% protein bound), which protects against DPP-4 degradation and reduces renal clearance, extending the plasma half-life to approximately 13 hours (vs ~2 minutes for native GLP-1)
- Pharmacokinetic profile: Maximum plasma concentration (Cmax) reached at 8-12 hours post-injection. Bioavailability is approximately 55% following subcutaneous injection. Steady state achieved after 3-5 days of once-daily dosing. Volume of distribution approximately 11-17 L
- Metabolism: Fully degraded endogenously like large proteins (no single organ as major elimination route). Metabolized by ubiquitous peptidases. No intact liraglutide detected in urine or feces. Half-life of ~13 hours supports once-daily dosing
- Dose proportionality: Exposure increases proportionally over the clinical dose range (0.6-1.8 mg for T2D; up to 3.0 mg for obesity)
- GLP-1 receptor agonism: Activates the GLP-1 receptor on pancreatic beta cells (glucose-dependent insulin secretion), alpha cells (glucagon suppression), brain (appetite suppression via hypothalamic and brainstem circuits), and GI tract (gastric emptying delay)
- Special populations: No clinically relevant dose adjustment needed for age, sex, body weight, ethnicity, or mild-to-moderate renal or hepatic impairment. Not recommended in severe renal impairment (limited data) or severe hepatic impairment
Study Design
Comprehensive narrative review synthesizing pharmacokinetic and pharmacodynamic data from Phase I-III clinical trials, population PK analyses, and special population studies. Reviews the molecular design rationale, absorption-distribution-metabolism-elimination profile, drug interaction potential, and population pharmacokinetics of liraglutide.
Limitations
- Narrative review format (not systematic) — potential for selective reporting of studies
- Authored by Novo Nordisk employees (manufacturer of liraglutide) — inherent conflict of interest
- Does not include comparative pharmacokinetic data vs other GLP-1 RAs (e.g., semaglutide, exenatide)
- Published before Saxenda (3.0 mg) pharmacokinetic data was as extensive; focuses primarily on Victoza (1.8 mg) PK data
- Limited discussion of immunogenicity and anti-drug antibody formation
Clinical Relevance
This review provides the definitive pharmacokinetic reference for liraglutide, essential for understanding its once-daily dosing rationale and clinical behavior. The detailed explanation of how the C-16 fatty acid acylation strategy extends the half-life from 2 minutes (native GLP-1) to 13 hours is fundamental to understanding the entire acylated GLP-1 RA drug class, including semaglutide (which uses a longer C-18 fatty di-acid chain to achieve weekly dosing with a ~168-hour half-life). The lack of need for dose adjustment in most special populations simplifies clinical prescribing. Understanding the albumin-binding mechanism is critical for practitioners comparing liraglutide to semaglutide and other GLP-1 RAs.
Related
#research #narrative-review #liraglutide #evidence-level-V #metabolic